Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 276

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

From GOLD 0 to Pre-COPD

Open access
Han, MeiLan K., Agusti, Alvar, Celli, Bartolome R., Criner, Gerard J., Halpin, David M. G., Roche, Nicolas, Papi, Alberto, Stockley, Robert A., Wedzicha, Jadwiga, Vogelmeier, Claus F.·2021·American Journal of Respiratory and Critical Care Medicine

Abstract

The diagnosis of chronic obstructive pulmonary disease (COPD) currently requires the demonstration of poorly reversible airflow limitation, defined as a post-bronchodilator FEV1/FVC <0.7 (1–3). Although some have argued that the lower limit of normal rather than a fixed value to define obstruction may be more accurate and theoretically more appropriate, recent pooled data from multiple NIH cohorts demonstrate that the fixed FEV1/FVC ratio <0.70 provides discrimination of COPD-related hospitalization and mortality that is equal to or better than other thresholds and the lower limit of normal (4). At present, FEV1/FVC remains the most robust and widely available marker of airflow limitation (5), although it may be less sensitive than some other measures (e.g., forced oscillometry). Likewise, FEV1 is one of the most powerful predictors of clinically relevant outcomes, including symptoms, exacerbations, and mortality (6, 7). Spirometry is inexpensive and widely available, even in many developing countries. Yet, at the same time, at an individual level, FEV1 may not fully indicate the extent of disease severity and progression, which may instead be manifest by symptoms, exacerbations, and increased risk of death. Furthermore, significant lung damage may have already occurred before abnormalities in FEV1 are evident. Identifying individuals who will eventually develop airflow obstruction consistent with a diagnosis of COPD may enable therapeutic interventions with the potential to modify the course of disease. In 2001, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease, proposed an “at-risk” stage (GOLD stage 0). It was defined by the presence of risk factors (smoking) and symptoms (chronic cough and sputum production) in the absence of spirometric abnormalities that cross the diagnostic threshold for COPD (3). This category was later abandoned because not all these individuals progressed to COPD (8). In retrospect, this may not have been the best decision, as many other medical disciplines have adopted the concept of “predisease” status (e.g., prediabetes, prehypertension, precancer, or preeclampsia). In those disciplines, predisease does not imply that all will develop the disease, but rather, the classification identifies an especially at-risk population for closer follow-up and risk management. Here, we propose to adopt a similar concept in the field of COPD. As has been highlighted in the recent perspective by Martinez and colleagues (9, 10), more is becoming understood about the pathogenesis of early COPD and the importance of identifying such individuals, in particular, for the development of disease-modifying therapies. In this perspective, our goal is to review the evidence available today that supports the need for the recognition of individuals at risk for COPD and discuss whether it is time to consider the evolution of the GOLD stage 0 concept to that of “pre-COPD” from a clinically relevant perspective (11). Although not an official GOLD document, this manuscript was generated on the basis of discussions within the GOLD Science Committee for the purposes of engaging the scientific community around the concept of pre-COPD. Symptomatic individuals with “normal” spirometric results are a heterogeneous group with a variety of abnormalities, including cough, sputum production, dyspnea, exacerbation-like events, and radiographic features that in some cases are similar to the clinical and radiographic presentation of patients with spirometrically confirmed COPD (12, 13). In the COPDGene (Genetic Epidemiology of COPD) cohort, roughly 43% of smokers with a normal FEV1/FVC ratio had emphysema, gas trapping, or airway wall thickening on computed tomography (CT). Twenty-three percent of these individuals had a modified Medical Research Council (MRC) dyspnea score ≥2 compared with 4% of never-smokers and 22% of individuals with GOLD stage 1 COPD (12). Furthermore, chronic bronchitis symptoms among unobstructed participants are also associated with impaired quality of life, reduced walk distance, and increased exacerbation-like events (14). In SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study), another NIH-funded cohort of smokers, roughly half of the smokers without airflow obstruction had a COPD Assessment Test score ≥10 and exacerbation rates similar to those of symptomatic subjects at GOLD stages 1–2 (15). These symptomatic individuals without spirometrically defined obstruction also displayed airway wall thickening on CT and elevated airway mucin concentrations, pointing to a pathologic basis for their symptoms (16). Similar findings were also observed in the Canadian population-based CanCOLD (Canadian Cohort Obstructive Lung Disease) cohort in whom exacerbation-like events were again seen among individuals without airflow obstruction. These subjects also had worse h

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.202008-3328pp

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 276

Metadata

Authors
Han, M. K., Agusti, A., Celli, B. R., Criner, G. J., Halpin, D. M. G., Roche, N., Papi, A., Stockley, R. A., Wedzicha, J., & Vogelmeier, C. F.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2021-02-15
Volume
203
Issue
4
Pages
414-423
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W3102911407
Cited by
276
References
50
FWCI
14.04
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: From GOLD 0 to Pre-COPD. https://app.cochat.ai/papers/10.1164/rccm.202008-3328pp
The paper
Han, M. K., Agusti, A., Celli, B. R., Criner, G. J., Halpin, D. M. G., Roche, N., Papi, A., Stockley, R. A., Wedzicha, J., & Vogelmeier, C. F. (2021). From GOLD 0 to Pre-COPD. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.202008-3328pp

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.